Free tool
FAERS Monitor: Isordil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012093 or its brand name (Isordil, Isosorbide Dinitrate). Reports on generic versions are filed under their own applications.
Reports
8,622
Serious
7,030
82% of reports
Hospitalization
4,081
Death reported
1,283
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea931
- nausea829
- diarrhoea789
- fatigue774
- dizziness762
- vomiting690
- chest pain687
- pain642
- myocardial infarction641
- headache636
- malaise608
- pyrexia597
- pruritus571
- anxiety550
- arthralgia540
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 271 |
| 2005 | 273 |
| 2006 | 249 |
| 2007 | 289 |
| 2008 | 370 |
| 2009 | 259 |
| 2010 | 317 |
| 2011 | 738 |
| 2012 | 532 |
| 2013 | 227 |
| 2014 | 298 |
| 2015 | 298 |
| 2016 | 338 |
| 2017 | 387 |
| 2018 | 441 |
| 2019 | 420 |
| 2020 | 409 |
| 2021 | 389 |
| 2022 | 353 |
| 2023 | 629 |
| 2024 | 399 |
| 2025 | 458 |
| 2026 | 276 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,537 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chest painSignal | 687 | 9.1 | 8.4 | 4,956 |
| myocardial infarctionSignal | 641 | 9.0 | 8.3 | 4,566 |
| anxietySignal | 550 | 4.7 | 4.4 | 1,629 |
| pyrexiaSignal | 597 | 4.2 | 3.9 | 1,482 |
| dyspnoeaSignal | 931 | 4.0 | 3.8 | 2,161 |
| dizzinessSignal | 762 | 3.7 | 3.5 | 1,555 |
| pruritusSignal | 571 | 3.6 | 3.4 | 1,103 |
| vomitingSignal | 690 | 3.6 | 3.3 | 1,310 |
| malaiseSignal | 608 | 3.4 | 3.1 | 1,040 |
| arthralgiaSignal | 540 | 3.2 | 2.9 | 816 |
| diarrhoeaSignal | 789 | 3.0 | 2.8 | 1,071 |
| nauseaSignal | 829 | 2.6 | 2.4 | 814 |
| painSignal | 642 | 2.6 | 2.4 | 621 |
| headacheSignal | 636 | 2.5 | 2.3 | 575 |
| fatigueSignal | 774 | 2.4 | 2.3 | 672 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.